Clinical Trial Update: A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating asundexian to prevent ischemic stroke and high-risk transient ischemic attack after an acute ischemic stroke or high-risk TIA has compl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke
• Transient Ischemic Attack

Drugs mentioned

• Asundexian (asundexian)

Snippet

Sponsor: Bayer | Conditions: Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke | Phase 3 | Status: COMPLETED